Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Net Income of -$38.55 million for fiscal year 2025.
SUPERNUS PHARMACEUTICALS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$38.55M | -152.2% |
| 2024 | $73.86M | +5512.8% |
| 2023 | $1.32M | -97.8% |
| 2022 | $60.71M | +13.6% |
| 2021 | $53.42M | -57.9% |
| 2020 | $126.95M | +12.3% |
| 2019 | $113.06M | +1.9% |
| 2018 | $110.99M | +93.8% |
| 2017 | $57.28M | -37.2% |
| 2016 | $91.22M | +554.2% |
| 2015 | $13.94M | +227.6% |
| 2014 | -$10.93M | +88.2% |
| 2013 | -$92.27M | -99.4% |
| 2012 | -$46.28M | -186.0% |
| 2011 | $53.81M | +239.9% |
| 2010 | -$38.46M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$45.12M | -217.2% | -300.5% |
| June 30, 2025 | $22.50M | +13.0% | +290.2% |
| March 31, 2025 | -$11.83M | -9637.9% | -130.7% |
| September 30, 2024 | $38.50M | +341.0% | +93.3% |
| June 30, 2024 | $19.92M | +2496.6% | +15961.3% |
| March 31, 2024 | $124.0K | -99.3% | +100.8% |
| September 30, 2023 | -$15.98M | -1013.4% | -1822.5% |
| June 30, 2023 | -$831.0K | -110.6% | -104.9% |
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -152.2% in Net Income compared to the prior fiscal year.
- Over the 2010–2025 period, SUPERNUS PHARMACEUTICALS, INC.’s net income has declined by 0.2% (from -$38.46 million to -$38.55 million).
- The most recent figure is from SUPERNUS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: